Opus Genetics
IRD
48 hedge funds and large institutions have $32.1M invested in Opus Genetics in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 4 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
95% more capital invested
Capital invested by funds: $16.5M → $32.1M (+$15.6M)
12% more funds holding
Funds holding: 43 → 48 (+5)
2.44% more ownership
Funds ownership: 29.34% → 31.78% (+2.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.19M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$435K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
+$159K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$141K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$158K |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$149K |
| 3 |
Millennium Management
New York
|
-$120K |
| 4 |
VF
Virtu Financial
New York
|
-$75K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$33.8K |
IRD Hedge Fund Activity: Q3 2025 in Review
48 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2025, worth a combined $32.1M — up 95% from $16.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new IRD positions and 4 closed out — a net gain of 6 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.19M. The largest seller was Royal Bank of Canada, cutting an estimated $158K.
- 48 institutional investors held Opus Genetics (IRD) as of Q3 2025, up from 43 in Q2 2025.
- Funds reported $32.1M of Opus Genetics stock for Q3 2025, up 95% quarter-over-quarter.
- 10 funds opened new Opus Genetics positions in Q3 2025 and 4 closed out, a net change of +6 holders.
- The largest Opus Genetics buyer in Q3 2025 was Adage Capital Partners, an estimated $1.19M added.
- The largest Opus Genetics seller in Q3 2025 was Royal Bank of Canada, an estimated $158K sold.
Based on aggregated 13F filings for Q3 2025.